Market Closed -
OTC Markets
14:20:59 2024-06-20 EDT
5-day change
1st Jan Change
0.0541
USD
-41.83%
-.--%
-45.95%
Neil Campbell Resigns as Director and President of Marizyme, Inc
March 19, 2021 at 09:00 am
On March 18, 2021, Dr. Neil Campbell resigned for good reason as a Director and President of Marizyme, Inc. ('Marizyme').
Marizyme, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
05-28
CI
Marizyme, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
05-13
CI
Marizyme, Inc. Announces Resignation of Julie Kampf from the Board of Directors
02-06
CI
Marizyme, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
11-14
CI
Marizyme, Inc. Announces FDA Clearance for Product, Duragraft
23-10-06
CI
Marizyme, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-18
CI
Marizyme, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-05-15
CI
Marizyme, Inc. announced a financing transaction
23-05-14
CI
Marizyme, Inc. Announces IP Developments for DuraGraft and its Pipeline of Products
23-05-10
CI
Marizyme, Inc. announced that it has received $0.265216 million in funding
23-05-09
CI
Marizyme, Inc. announced that it expects to receive $0.265216 million in funding
23-04-17
CI
Marizyme, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
23-03-24
CI
Marizyme, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
23-03-24
CI
Marizyme, Inc. Auditor Raises 'Going Concern' Doubt
23-03-23
CI
Marizyme, Inc. announced that it expects to receive $1 million in funding from Walleye Capital LLC
23-02-06
CI
Marizyme, Inc. announced that it has received $0.75 million in funding
22-12-27
CI
Marizyme, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
22-11-14
CI
Marizyme, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
22-08-15
CI
Marizyme, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
22-05-16
CI
Marizyme, Inc. Appoints Michael R. Stewart to the Board, Effective June 1, 2022
22-05-12
CI
Marizyme, Inc. Appoints Nilesh Patel to Board as Director
22-04-25
CI
Marizyme, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
22-03-31
CI
Marizyme, Inc. Auditor Raises 'Going Concern' Doubt
22-03-30
CI
MMarizyme, Inc. Announces Allowance of Patent Application for Duragraft® by United States Patent and Trademark Office
22-01-05
CI
Marizyme, Inc. Appoints David Barthel as Member of Board of Directors
21-12-23
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Marizyme, Inc. is a medical technology company. The Company is focused on cardiac and surgical care by delivering innovative solutions for coronary artery bypass graft (CABG) surgery and other surgical procedures. Its product DuraGraft, is a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, thereby reducing the incidence and complications of graft failure and improving clinical outcomes post bypass surgery. The Companyâs product under development includes MATLOC and MAR-FG-001. MATLOC is a lab-on-chip digital screening and diagnostic device platform being developed for quantitative chronic kidney disease (CKD) assessment. The MAR-FG-001 is a tumescent solution base for fat grafting procedures that is used for plastic and cosmetic surgeries in which fat is transferred from one area of the body to another to correct a defect, replace injured tissue, or to make cosmetic enhancements.
More about the company
1st Jan change
Capi.
-45.95% 7.13M +16.61% 121B +17.75% 110B +17.23% 25.98B -24.11% 19.27B -18.56% 15.99B -18.47% 15.66B -47.75% 14.5B +57.35% 14.47B +5.62% 13.91B
Bio Therapeutic Drugs
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
MARIZYME, INC. 
